Pancreatic ductal adenocarcinoma (PDAC) features a prominent stromal microenvironment
with remarkable cellular and spatial heterogeneity that meaningfully impacts disease …

The rising incidence and persistent dismal 5-year overall survival of pancreatic ductal
adenocarcinoma (PDAC) highlight the need for new effective systemic therapies …

Chimeric antigen receptor (CAR) T cell therapy has achieved remarkable success in
hematological malignancies but remains ineffective in solid tumors, due in part to CAR T cell …

Chimeric antigen receptor (CAR) T cells are ineffective against solid tumors with
immunosuppressive microenvironments. To overcome suppression, we engineered circuits …

Engineering chimeric antigen receptors (CAR) or T cell receptors (TCR) helps create
disease-specific T cells for targeted therapy, but the cost and rigor associated with …

Pancreatic ductal adenocarcinoma (PDA) is among the most immune-resistant tumor types.
Its unique genomic landscape shaped by oncogenic drivers promotes immune suppression …

Cancers are not composed merely of cancer cells alone; instead, they are complex
'ecosystems' comprising many different cell types and noncellular factors. The tumour stroma …

Here, we utilized spontaneous models of pancreatic and lung cancer to examine how
neoantigenicity shapes tumor immunity and progression. As expected, neoantigen …

Checkpoint blockade (CPB) therapy can elicit durable clinical responses by reactivating an
exhausted immune response. However, response rates remain limited, likely secondary to a …

Pancreatic ductal adenocarcinoma (PDAC) is projected to become the second deadliest
cancer in the United States by 2025, with 5-year survival at less than 10%. In other …